Fierce Pharma Asia—Hansoh's siRNA deals; J&J preps for Legend's CAR-T launch; Brii's COVID antibodies

China's Hansoh Pharma inked two siRNA partnerships. Johnson & Johnson intends to roll out a tailored patient support program for Legend Biotech's upcoming CAR-T therapy. Brii Biosciences' COVID-19 antibody combo could be a blockbuster opportunity, one analyst said. And more.

Related Keywords

China ,Japan ,Shanghai ,San Francisco ,California ,United States ,Japanese ,Chinese ,Raymond Stevens ,Calithera Biosciences ,Goeffrey Porges ,Serge Messerlian ,Chipscreen Biosciences ,Yoo Seok Hong ,Hansoh Pharma ,Brii Bioscience ,Merck Januvia ,Olix Pharmaceuticals ,Johnson ,Wave Life Sciences ,Legend Biotech Partnered ,Silence Therapeutics ,Legend Biotech ,Seok Hong ,Jiangsu Hansoh ,Ohnson Amp Johnson ,Makeda ,Lupin ,South Korea ,Licensing ,Ar T ,Patient Assistance Programs ,Covid 19 ,Antibody Drugs ,Non Small Cell Lung Cancer ,Chronic Disease ,Parkinson 039s Disease ,Initial Public Offering ,Drug Recall ,Type 2 Diabetes ,Pharma ,